Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non-small cell lung cancer
{{output}}
Background: Although immune checkpoint inhibitors (ICIs) have significantly improved overall survival (OS) for patients with metastatic non-small cell lung cancer (mNSCLC), there is a paucity of comparative effectiveness evidence... ...
